<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02051673</url>
  </required_header>
  <id_info>
    <org_study_id>ICT-7392-Compassionate Use</org_study_id>
    <nct_id>NCT02051673</nct_id>
  </id_info>
  <brief_title>Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)</brief_title>
  <official_title>Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Talaris Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Talaris Therapeutics Inc.</source>
  <brief_summary>
    <textblock>
      Four subjects were treated under compassionate use provisions under this study with&#xD;
      facilitating cell therapy (FCRx)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Four subjects were treated under compassionate use provisions under this study with&#xD;
      facilitating cell therapy (FCRx) and living donor kidney transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Renal Failure</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion</intervention_name>
    <description>Enriched Hematopoetic Stem Cell Infusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be between the ages of 18 and 65 years and meet the institution's&#xD;
             criteria for renal transplantation for end-organ failure&#xD;
&#xD;
          -  Patient is receiving first renal transplant&#xD;
&#xD;
          -  Patient is receiving a renal transplant only&#xD;
&#xD;
          -  The crossmatch is negative between donor and recipient&#xD;
&#xD;
          -  Women who are of child bearing potential must have a negative pregnancy test (urine&#xD;
             test is acceptable) within 48 hours of initiating total body irradiation (TBI) and&#xD;
             agree to use reliable contraception for 1 year following transplant&#xD;
&#xD;
          -  Potential donors who are women of child bearing potential must have a negative&#xD;
             pregnancy test (urine test is acceptable) within 48 hours prior to receiving&#xD;
             Granulocyte colony-stimulating factor (G-CSF)&#xD;
&#xD;
          -  No evidence of donor-specific antibody presently or historically&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically active bacterial, fungal, viral or parasitic infection&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Clinical or serologic evidence of viral infection which would preclude the recipient&#xD;
             from receiving a kidney transplant&#xD;
&#xD;
          -  Previous radiation therapy at a dose which would preclude TBI&#xD;
&#xD;
          -  Positive crossmatch between donor and recipient&#xD;
&#xD;
          -  Evidence for immunologic memory against donor&#xD;
&#xD;
          -  BMI &gt;35 or &lt;18&#xD;
&#xD;
          -  Re-transplant&#xD;
&#xD;
          -  Positive serologies for hepatitis B virus (HBV), hepatitis C virus (HCV), HIV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Suzanne T Ildstad, MD</last_name>
    <role>Study Director</role>
    <affiliation>Talaris Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>January 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2014</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

